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Abstract
The main objective of this work was to show the potential of the optimization of top-down wet planetary bead milling process parameters 
(milling speed, process time and size of the milling medium) by Design Of Experiments (DOE) approach for the development of 
albendazole	(ABZ)	containing	nanosuspension	with	improved	dissolution.	In	addition,	the	influence	of	process	parameters	(capacity	of	
milling container, applied volume of milling beads, size of the milling medium, milling speed, milling time) on ABZ polymorphic transition 
has	also	been	investigated.	The	optimized,	milled	formula	yielded	~	145.39	times	reduction	in	mean	particle	size	(182.200 ± 1.3130 nm)	
compared to unmilled dispersion, which demonstrated 13.50 times gain in mean dissolution rate value compared to the unmilled 
dispersion in medium at pH = 1.2. No lag time values were observed in the dissolution kinetics of the nanosuspension in comparison 
with	the	unmilled	samples.	Moreover,	maximal	mean	solubility	value	was	also	 improved	by	1.45 times	compared	to	the	unmilled	
suspension,	in	medium	at	pH	=	6.8,	supporting	the	significance	of	the	Ostwald-Freundlich	equation.	Diffraction	pattern	comparisons	
have indicated a polymorphic transition of albendazole to Form II, which was more pronounced in smaller container at high milling 
speed values and prolonged operations.
Keywords
albendazole	 nanosuspension,	 wet	 media	 milling,	 dissolution	 improvement,	 Powder	 X-Ray	 Diffractometry	 (PXRD),	 Design	 Of	
Experiments (DOE)
1 Introduction
One of the major obstacles of the development of highly 
potent new drug candidates is the poor water solubility of 
these compounds, which hinders their therapeutic appli-
cation [1]. Albendazole (ABZ) is a benzimidazoles-type, 
broad-spectrum anthelmintic for the treatment of intestinal 
helminth infections [2, 3], also showed promising results in 
chronic systemic therapies of cyst and echinococcus infes-
tations [4]. This compound has a pH dependent, poor water 
solubility, a minimal of 0.016 mg/ml in pH = 6.0 buffers 
and a maximal of 0.376 mg/ml in medium at pH = 1.2 [5]. 
It has an octanol-water partition coefficient (log P) value of 
3.83 [6], which is high, according to the Biopharmaceutical 
Classification  System  (BCS)  drug  permeability  classifi-
cations [7]. As a result, ABZ is classified as a BCS Class 
II drug [8]. The melting point of ABZ is high, it was 
197.7 °C according to our investigations [9], in agreement 
with other experiment in the literature 200–230 °C [10]. 
The effective dose of this compound is relatively high 
(200 mg human) [11] 7.5–10 mg/kg cattle and 5 mg/kg 
sheep in animal healthcare [2, 3]. Pragmatic approaches 
for chemo-therapy of hydatid patients necessitate focusing 
on improved transport, targeting, modulation of the phys-
icochemical parameters and metabolic decomposition of 
benzimidazoles [12]. An excellent review on recrystalli-
zations,  identification,  stability and solubility evaluations 
of enantiotropically related albendazole polymorphs were 
performed by Pranzo et al. [13]. According to the authors 
there are two polymorphs available for ABZ, Form I (com-
mercially available form) and Form II (recrystallized from 
N,N-dimethylformamide). Both forms proved to be physi-
cally quite stable, likely due to a high-energy barrier for the 
activation of the interconversion. Temperature dependent 
solubility studies revealed, that on 25 °C solubility of Form I 
is better, than Form II. They also reported, that 80 °C is the 
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interception of the solubility vs. temperature curves, where 
the solid–solid transition is beginning. This observation 
confirms, that Form I represent the metastable polymorphs 
at ambient temperature. Application of a metastable Form I 
may be advantageous (e. g., for exploiting higher solubility 
in the gastrointestinal tract) only when the kinetics of con-
version would be slow, namely when the energetic barrier 
Form  I →  Form  II  cannot  be  overcome  during  specific 
storage conditions. In this respect, the metastable phase 
should be kept cool and dry and should not be  too finely 
subdivided [13].
Pharmaceutical  nanosuspension  is  defined  as  colloi-
dal, biphasic systems, in which solid drug particles are 
very finely dispersed  in  an  aqueous vehicle, without  any 
matrix material, stabilized by surfactants and/or poly-
mers [14, 15]. The particle size of the solid particles in 
nanosuspensions is usually less than 1 μm with a mean par-
ticle size ranging between 200 and 600 nm [16]. The poten-
tial benefits of  the nanosuspension  technology  for poorly 
soluble drug delivery are increased drug dissolution rate, 
increased rate and extent of absorption, hence the bioavail-
ability of a drug (area under plasma concentration versus 
time curve, onset time, peak drug level), reduced variabil-
ity, reduced fed/fasted effects. They have low incidence of 
side effects caused by the excipients, increased resistance 
to hydrolysis, to oxidation and physical stability to settling. 
Compared to microparticles nanoparticles have another 
outstanding feature, which is the increased adhesiveness 
to tissues, usually due to an increased contact area of small 
particles versus large particles (at identical total particle 
mass), which lead to improved oral absorption and pene-
tration capability in case of topical routes of administra-
tions [17]. Reduced administration volumes are essential 
for intramuscular, subcutaneous, and ophthalmic delivery. 
By surface modifications they can also provide the passive 
targeting [18–20]. The ease of scale-up and low bath-to-
batch variability could be mentioned as the main advan-
tages of the utilizations of nanosuspensions, while the most 
common disadvantages are high energy investment during 
manufacturing, immunotoxicity and non-specific uptake in 
reticuloendothelial system (RES) organs [18–21]. There are 
two converse methods available for the manufacturing of 
nanosuspensions. The assembling ‘bottom-up’ approaches, 
starting from molecules and building up to nano-sized 
particles, including microprecipitation, microemulsion 
and melt emulsification. The other group of techniques is 
referred to as ‘top-down’ variants, which are disintegration 
approaches from large particles, usually microparticles to 
nanoparticles, including high-pressure homogenization, 
media milling and there are combination methods as well, 
merging the advantages of both methods [22, 23].
Post processing nanosuspensions into solid dosage 
forms in order to improve physical stability has shown 
great interest e. g. spray-drying [24, 25], freeze-dry-
ing [26], fluid bed coating [27], electro-spraying [28] and 
hot melt extrusion [29] techniques have been successfully 
applied developing various formulations containing redis-
persable nanocrystals. An overview of albendazole con-
taining nanosuspension formulations available in the liter-
ature have been summarized in Table 1.
Central Composite Design (CCD) is a response surface 
design which provides information on direct effects, pair 
wise interaction effects and curvilinear variable effects 
and is widely used for formulation and process optimi-
zation  in  the  field  of  pharmaceutical  product  develop-
ment [35]. Desirability is an objective function that ranges 
from zero outside of the limits to one at the goal. The opti-
mization module searches for a combination of factor lev-
els that simultaneously satisfy the criteria placed on each of 
the responses and factors. To include a response in the opti-
mization  criteria  it must  have  a model fit  through  analy-
sis or supplied via an equation only simulation. Factors are 
Table 1 Albendazole nanosuspension formulation approaches 
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Fülöp et al.
Period. Polytech. Chem. Eng., 64(4), pp. 401–420, 2020 |403
automatically included "in range". Numerical optimization 
uses the models to search the factor space for the best trade-
offs to achieve multiple goals. The numerical optimization 
finds  a  point,  that  maximizes  the  desirability  function. 
The characteristics of a goal may be altered by adjusting 
the weight or importance. For several responses and fac-
tors, all goals get combined into one desirability function. 
People become distracted by trying to always get a very 
high desirability value. The value is completely dependent 
on how closely the lower and upper limits are set relative 
to the actual optimum. The goal of optimization is to find a 
good set of conditions that will meet all the goals, not to get 
to a desirability value of 1.0. Desirability is simply a math-
ematical method to find the optimum. Contour, 3D surface, 
and perturbation plots of the desirability function at each 
optimum can be used to explore the function in the fac-
tor space [36]. The desirability function can be applied for 
the optimization of multiple response processes finding the 
levels of the controllable independent factors, that provide 
the most desirable Yi response values. The di (Yi) uses num-
bers to the possible response Yi, where di (Yi) = 1 represents 
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This article is divided into three different sections. 
The first  section emphasizes  the potential of  the optimi-
zation of loading composition and formulation factors of 
the top down wet planetary bead milling method (Fig. 1). 
Our goal was to prepare ABZ nanocrystals with size dis-
tribution parameters similar to those, produced by novel 
modified  variant  of  the  so-called  emulsion  crosslinking 
volatile method [33, 34].
Process parameter optimization was performed by 
design of experiments (DOE) approach, which is a useful 
tool for the Quality by Design (QbD) concept [37]. There 
are numerous DOE approaches available for nanosuspen-
sion development e. g. evaluation of one variable at a time 
(OVAT) – type [38], 22 – type factorial [39], 32 – type fac-
torial [40, 41], Box-Behnken – types [38,42]. 
Utilization of the microhydrodynamic models for milling 
parameter optimization, ideal milling beads selection and 
describing their fluctuating motion during high energy Wet 
Stirred Media Milling (WSSM) process [43] has also gained 
attention in recent years [44]. Particle size distributions have 
been defined by dynamic light scattering and laser diffrac-
tion methods. Long term physical stability determination of 
the optimized nanosuspension formula as a liquid dosage 
form was not investigated in this study, only a short 56 days 
long demonstration was included. The potential stabiliza-
tion principal as a reconstitutable solidified dosage form has 
already been reported in a previous article [9].
Section 2 focuses on in vitro solubility and dissolution 
studies, which describes the impact of the particle size 
reduction and the solubilization on the water solubility of 
albendazole along with the dissolution rate values in vari-
ous aqueous-based pH buffer solutions.
Finally,  Section  4  describes  the  influence  of  process 
parameters (capacity of the milling container, size of the 
milling medium, applied volume of the milling beads, 
milling speed, milling time) on ABZ polymorphism. 
It has already been reported, that mechanical stress and 
other sources of excess energy such as heat are inherent to 
milling and often lead to significant changes on the physi-
cal and chemical properties of pharmaceutical crystalline 
solids. Partial or complete transformation to the amor-
phous form, polymorphic transformations, and changes in 
chemical reactivity are among the frequently encountered 
changes produced by milling [45]. The presence of solvent 
can have drastic influence on the outcome of the mechan-
ical treatment and can greatly affect the nature of the 
resulting material [46–50]. Crystal defects are practically 
unavoidable in pharmaceutical processing. Fundamental 
Fig. 1 Optimization of quality attributes based on design of experiments
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understanding of milling induced disorder will lead to a 
better process control and more consistent product per-
formance  [45].  Solid  state  characterization of  raw mate-
rial albendazole and albendazole processed in milled 
suspensions after drying were performed by x-ray pow-
der diffraction analysis. The novelty of this is work is the 
identification of extreme milling conditions, where disad-
vantageous ABZ Form I → Form II conversion is realized, 
giving a hint to formulation scientists to avoid these con-
ditions during ABZ nanosuspension development by wet 
planetary bead milling techniques.
1.1 Theoretical
The Ostwald-Freundlich equation (Eq. (2)) directly 



















where Cs is the saturation solubility, Cα is the solubility of the 
solid consisting of large particles, σ is the interfacial tension 
of substance, V is the molar volume of the particle material, 
R is the gas constant, T is the absolute temperature, ρ is the 
true density of the solid and r is the radius of the particle.
It describes, that the saturation solubility (Cs) of a drug 
increases with a decrease in the particle size (r). However, this 
effect is not substantial for larger particles, but will be pro-
nounced for materials that have a mean particle size of less 
than 1-2 µm, especially well under 200 nm [17].
For volume weighted particle size distributions, such as 
those measured by laser diffraction, it is often convenient 
to report parameters based upon the maximum particle size 
for a given percentage volume of the sample [52]. In this 
article the volume weighted mean particle size (D[4,3]) 
has been chosen as one of the dependent variables in 
3-factor 3-level central composite design (face centered of 
alpha 1) over the median particle size d50 and 90 % cumu-
lative undersize particle size d90. The volume weighted 
mean particle size or volume moment mean (De Brouckere 
Mean Diameter) is relevant for many samples as it reflects 
the size of those particles which constitute the bulk of the 
sample volume. It is most sensitive to the presence of large 




















The Di value for each screened channel is the geometric 
mean, the square root of upper multiplied by the lower diam-
eters. For the numerator the geometric Di should be taken 
to the fourth power and multiplied by the percentage in that 
channel, summed over all channels. For the denominator the 
geometric Di should be taken to the third power times the 
percent in that channel, summed over all channels [54, 55].
2 Materials and methods
2.1 Materials
Albendazole EP (micronized), (Sequent Scientific Ltd., India) 
was utilized as model drug for wet planetary bead milling 
operations. The  influence of  various  surface-active  agents 
on wet milling have been compared such as Polysorbate 80 
(Tween 80) (Molar Chemicals Kft., Hungary), polysorbate 
20 (Tween 20) (Molar Chemicals Kft., Hungary), sodium 
laurylsulphate (Molar Chemicals Kft., Hungary), hypromel-
lose (Benecel™ E3 pharm) (Ashland Inc., USA), poloxamer 
407 (Lutrol® F127), poloxamer 188 (Lutrol®  F68)  (BASF, 
Germany), polyoxyl 35 hydrogenated castor oil (Kolliphor® 
EL), polyoxyl 40 hydrogenated castor oil (Kolliphor® RH40) 
(Sigma-Aldrich,  USA).  Dimethylpolysiloxane  (Foamsol) 
(Kokoferm Kft., Hungary) was applied as antifoaming 
agent (AF).
2.2 Surfactant assisted planetary bead milling process
Determination of the preliminary composition of presus-
pension regarding to drug loading (albendazole concentra-
tion) and surfactants is one of the utmost importance during 
nanosuspension formulation development [56]. Then critical 
process parameter optimization of the wet planetary bead 
milling process was applied. All equipment and accessories 
(planetary ball mill, containers, beads and sieves) were pro-
vided by (Retsch Technology GmbH., Germany). PM 100 
planetary ball mill, with stainless steel containers of 12 ml, 
50 ml and 500 ml capacity and zirconium-dioxide beads 
with sizes of d = 0.1 mm, d = 0.3 mm, d = 1.0 mm were 
utilized for milling. Stainless steel sieves, with mesh sizes 
of d = 800 µm, d = 180 µm and d = 63 μm, were applied to 
separate the beads from the milled suspensions by simply 
pouring the content of containers onto these sieves, avoiding 
aggregation by vibration. Milling temperature control was 
part of every milling experiment and was registered with 
an analog thermometer (Alla® France Sarl, France), which 
precision and traceability was certified. At-line control was 
performed immediately after milling programs have ended, 
top of the milling container was removed, the analog ther-
mometer was inserted directly into the container and maxi-
mal milling temperature values were registered.
Fülöp et al.
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2.3 Ideal loading composition determination for wet 
media milling of albendazole
Loading composition optimization evaluations were 
carried out in the smallest laboratory sized container 
(12 ml), with batch sizes of 8.00 g, at high milling speed 
(500 rpm), also with high volume of applied milling 
beads (4.8 ml), while various milling programs, continu-
ous operations were compared to cyclic ones, comprised 
of equally long milling and cooldown cycles, (5–5 min-
utes and 10–10 minutes, on–off) total process time was 
60 minutes. For determination of albendazole loadings 
1.00 % (w/w), 3.00 % (w/w) and 4.00 % (w/w) were inves-
tigated.  The  influence  of  the  surface-active  agents  and 
polymers on wet milling of albendazole were compared 
in concentrations of 0.40 % (w/w). Best performed emul-
sifier concentration was screened between  the  ranges of 
0.30 % (w/w) to 1.00 % (w/w), application of antifoam-
ing agent dimethylpolysiloxane at higher concentrations 
(> 0.50 % (w/w)) was also involved. Results were eval-
uated  by  the  following  criteria:  maximizing  submicron 
sized fraction (%), while minimizing volume-weighted 
mean particle size D[4,3]) (µm), and Span values (polydis-
persity or width of particle size distributions).
2.4 Particle size distribution and zeta-potential analysis
Particle size distributions of milled albendazole suspensions 
have been determined by both Laser Diffractometry (LD) 
and Dynamic Light Scattering (DLS). Sample preparations 
involved dispersing 100 µl of milled suspensions dropwise 
in 100 ml of demineralized water at a mixing speed of 1500 
rpm poured into Mastersizer Hydro SM small volume dis-
persion unit, which yielded 10 % laser obscurations. Sample 
absorbances have been measured prior to every particle siz-
ing by an 8453-type, single beam UV-Vis spectrophotome-
ter, (Agilent Technologies, USA) on wavelength λmax = 633 
nm, which is the wavelength of both red He-Ne laser beams, 
found in instruments Mastersizer 2000 laser diffractometer 
and Zetasizer nano ZS™, (Malvern Instruments Ltd., UK) 
two angle particle and molecular size analyzer. Laser dif-
fraction measurement were performed based on Mie scat-
tering theory. Preset measurement parameters included 
the refractive index of albendazole 1.634, refractive index 
of dispersant water 1.333 and true density of albendazole 
1.3 g ml. True density of materials  is required for specific 
surface area calculations from size distribution parameters. 
General purpose measurement with enhanced sensitivity 
mode was utilized, which is suitable for sample characteri-
zations containing irregular shaped particles. Every sample 
was measured five times individually and the mean ± stan-
dard deviation values were reported in the results section. 
Recorded parameters were submicron sized fractions (%), 
volume-weighted mean particle sizes (D[4,3] (μm)) and span 
values. Submicron sized fractions (%) were calculated from 
the cumulative undersize distribution curves. Each measure-
ment took 20 seconds to perform suggested by the Malvern 
diffraction application v.5.60.10.0 (Malvern Instrument Ltd., 
UK), to allow slow moving larger aggregates to pass through 
the detector array.
Final, optimized nanosuspension formula has also been 
characterized by DLS method as well. For that, 1 ml of dis-
persed, diluted nanosuspension (described above) has been 
withdrawn from the small volume dispersion unit and were 
poured into a PCS 1115 glass sizing cuvette with square aper-
ture  (Malvern  Instruments  Ltd.,  UK).  DLS  measurement 
settings:  Automatic,  NIBS  (Non-Invasive-Backscattering) 
mode with laser angle 173°, 28–32 sub runs/measurement, 
run durations: 10 s. Sample chamber was heated to 25.0 °C, 
and equilibration time was 300 seconds. Automatic laser 
positioning and attenuation have been predescribed for DTS 
Application v.7.11.07073 (Malvern Instruments Ltd., UK), 
also  five  individual  measurements  were  performed,  for 
every sample and the mean ± standard deviation values 
were reported for all the DLS parameters, including: inten-
sity-weighted mean hydrodynamic diameter (Z AVG d) and 
Polydispersity Index (PDI) values in this article. In drug 
delivery applications a PDI value of less, than 0.3 is preferred 
for homogenous, narrow particle size distributions [57].
Zeta-potential gives certain information about the sur-
face charge properties and further the long-term phys-
ical stability of the nanosuspensions. In order to obtain 
an electrostatically stabilized nanosuspension, a min-
imum zeta potential of ± 30 mV is required. In case of 
a combination of electrostatic and steric stabilization, a 
minimum zeta potential of ± 20 mV is desirable [58–60]. 
Zeta-potential values were also recorded with Zetasizer 
nano ZS™ Electrostatic Light Scattering  (ELS) method. 
Sample preparations involved carefully pouring 750 µl of 
diluted  milled  samples  into  DTS  1070  capillary  folded, 
disposable Zeta cells (Malvern Instruments Ltd., UK) to 
avoid the formation of bubbles in capillaries, which can 
mislead measurement results.
Zeta-potential distributions were registered in auto-
matic mode from 5 parallels after 300 seconds equilibra-
tion time at 25 °C and the mean ± standard deviation val-
ues were reported. Dispersant viscosity correction was not 
necessary, because surfactant concentration and milled 
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active content of diluted samples was 0.0005 % (w/w) 
and 0.00365 % (w/w) respectively, which had negligible 
impact on dispersant viscosity.
2.5 Process parameter optimization of wet-milling by 
factorial design and desirability approach
Out of all the experimental designs, Central Composite 
Designs (CCD) have been extensively used to optimiza-
tion of manufacturing processes. 
In order to characterize the relationship between for-
mulation factors and their impact on the output variables 
response surface methodology based on face centered cen-
tral composite design was utilized.
The sizes of zirconia beads, the milling speed and the 
milling time values can significantly influence the quality 
performance of nanosuspensions. In this study these were 
the analyzed formulation variables. Milling experiments 
were carried out in 500 ml containers, with two different 
volumes of milling beads (100 ml and 200 ml) as category 
factors, where batch sizes were 425.5649 g and 476.1498 g 
respectively. A three-level (+1, 0, -1) factorial design 
for the optimization of the independent variables with 
32–32 runs (5–5 center points) was applied to each cate-
gory. Submicron sized fraction (%) (Y1), volume-weighted 
mean particle size (D[4,3]) (µm) (Y2), span of particle size 
distributions (Y3), zeta-potential (mV) (Y4) and milling 
temperature (°C) (Y5) values were selected as responses 
(dependent variables) (Table 2). Experiments were run 
in random order to increase the predictability of the qua-
dratic models. The following 3-level factorial polynomial 
equation was fitted to the measurement data (Eq. (4)):
Y b b X b X b X b X X
b X X b X X b X b X
n = + + + +
+ + + +
0 1 1 2 2 3 3 12 1 2
13 1 3 23 2 3 11 1
2
22 2





where Yn were the dependent variables; b0 was the inter-
cept,  the  arithmetic  mean  of  all  quantified  outcomes  of 
32 runs; b1, b2, b3 were the individual polynomial coeffi-
cients describing  the  influence of each parameter on  the 
outcome; b12, b13, b23 were the coefficients of  the  interac-
tion functions; b11, b22, b33 were the coefficients of the qua-
dratic functions; X1, X2, X3 values were the independent 
variables, where X1 represented the milling time (20, 40 
and 60 minutes long programs were screened), X2 repre-
sented the milling speed (effect of 200, 400 and 600 rpm 
on wet milling were investigated) and X3 represented the 
sizes of milling beads (effect of d = 0.1, d = 0.3 and d = 1.0 
mm sized zirconia beads on wet milling were compared).
The optimization and statistical experiments were 
designed and evaluated using the Design-Expert® software 
version 7.0.0 (Stat-Ease® Inc., USA). A quadratic polyno-
mial 3-level factorial response surface design type has 
been predescribed, with no blocks. 
Numerical optimization preset evaluation conditions 
included: maximizing submicron sized fraction, with tar-
get set to 100 % , with importance set to the maximal 5 (+), 
minimizing volume-weighted mean particle size, where 
upper target was D[4,3]) (µm) < 0.600 µm, importance 
5 (+) maximal, minimizing span (width of particle size 
distributions), importance 3 (+), minimizing zeta-poten-
tial (mV), where upper target was < -30 mV, importance 
5 (+) maximal and also minimizing milling temperature 
(°C) values, with upper target of < 40 °C, importance 5 (+) 
maximal. For end-product process parameter selection 
economical purposes were also taken into consideration, 
such as maximizing loading and yield, while minimizing 
energy consumption (milling speed and process time) with 
importance set to 3 (+) (Table 3).
2.6 Thermodynamic solubility studies
Thermodynamic solubility studies were determined using a 
slightly modified version of  the classical  saturation shake-
flask method in dissolution media at pH = 1.2 (0.1 N hydro-
chloric acid), pH = 4.5 (phosphate-buffer) and pH = 6.8 
(phosphate-buffer). Albendazole powder (10 mg), milled and 
unmilled surfactant dispersions containing 10 mg of alben-
dazole were poured into 10 ml volumetric vials, an addi-
tional 5 ml of dissolution media were added to the samples.
Vials were sealed and the contents of the vials were 
mixed at speed 800 rpm and heated to 37 °C with heat-
able magnetic stirrer MS-H-S10 (DLAB Instruments Ltd., 
China) and magnetic stirrer bars for 24 hours, then sed-
imentation was utilized for another 24 hours on 37 °C 
as well. It has already been reported by Baka et al. [61], 
that the safest way for phase separation is sedimentation, 
although diluted milled samples formed stable colloidal 
systems, where sedimentation was not enough for phase 
separation [61]. Thus, aliquots were taken and centri-
fuged at 14000 rpm for 15 min using a MicroGen 16-type 
(Herolab GmbH, Germany) centrifuge. To avoid dissolved 
ABZ absorption of syringe mounted membrane filters and 
to increase precision and reproducibility, membrane filter-
ing has been ignored, only centrifugation had been utilized 
for phase separation [62]. Complete phase separation has 
been  confirmed  by  transmittance  analysis  and Dynamic 
Light  Scattering  particle  sizing  methods.  Three  clean 
supernatants were taken and measured. The mean thermo-
dynamic solubility values (µg/ml) ± SDs were calculated 
from the linear calibrations in each dissolution medium 
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and were determined by spectrophotometry on the absorp-
tion maximum of albendazole at wavelength λmax = 291 
nm, measured by an 8453-type UV-Vis spectrophotometer 
(Agilent Technologies, USA).
2.7 Iv-vitro dissolution study of nanosuspensions and 
surfactant dispersions
Dissolution tests were performed using Hanson 
SR  -  8  Plus™  Dissolution  Test  Station  (Teledyne  Hanson 
Research  Inc., USA)  by USP  apparatus  2  (paddles) meth-
ods at 75 rpm rotation speeds and 37 ± 0.2 °C bath tem-
peratures. For sampling Autoplus Maximizer and Autoplus 
MultiFill, (Teledyne Hanson Research Inc., USA) were uti-
lized. Dissolution kinetics of optimized nanosuspensions, 
unmilled surfactant dispersions and raw albendazole pow-
ders were investigated in 900 ml aqueous-based buffer solu-
tions at pH = 1.2 (Ph. Eur. 9) (in doses of 200 mg), pH = 4.5 
phosphate buffer solution (Ph. Eur. 9) (in doses of 100 mg) 
and pH = 6.8 phosphate buffer solution (Ph. Eur. 9) (in doses 
of 100 mg). At predetermined time-points 5 ml samples 
were  withdrawn  from  the  vessels  and  filtered  through 
P/N FIL10S-HR 10 µm pore sized full flow membrane fil-
ters  (Quality Lab Accessories L.L.C., USA) placed on  the 
e-probes.  Samples were  collected  in  offline mode  to  16  x 
100–type test tube holder rack. After every sampling, media 
replacement was accomplished by 5 ml of fresh buffer solu-
tions. Collected samples were filtered through 0.1 µm pore 
sized  polyether  sulfonate  (PES)  syringe  membrane  filters 
(Nantong FilterBio Membrane Co. Ltd., China) prior to mea-
surements, in order to remove undissolved particles. 
Dissolution studies were performed in triplicates and 
the cumulative drug release (%) mean values ± SDs were 
calculated from the linear calibrations in the defined dis-
solution media, determined by UV-Vis spectrophotometry 
on the absorption maximum of albendazole at wavelength 




differences between measured and calculated values), fol-
lowed by Weibull-model fitting.
2.8 Maximizing albendazole yield after optimized 
milling process
Economic considerations necessitate the maximization of 
yield for cost effective manufacturing. In order to do so, 
several washing experiments have been performed and 
compared by an additional 16.66 % (w/w) of suspension 
loading of surfactant solution added to separated beads in 
milling container with 500 ml capacity, surfactant solu-
tion consisted of 0.5 % (w/w) Tween 80 and 0.01 % (v/v) 
of antifoaming agent dimethylpolysiloxane. The operation 
was repeated by the addition of twice 16.66 % (w/w) con-
tainer mass loading, followed by 33.33 % (w/w), then twice 
of 33.33 % (w/w). An additional milling cycle was applied 
after every surfactant solution addition to separated beads 
on 300 rpm milling speed for 5 minutes followed by another 
separation on stainless steel sieve with mesh size of d = 63 
μm.  Collected  and  diluted  nanosuspensions  were  mixed 
with milled ones on heatable magnetic  stirrer MS-H-S10 
(DLAB Instruments Ltd., China) at a stirring speed of 600 
rpm, with a homogenization time of 5 minutes. Drug load-
ing, particle sizing and zeta-potential determinations were 
performed after each washing experiment in order to study 
Table 2 Independent variables with levels and goals for the construction of DOE




−1 0 +1 −1 0 +1
Milling time (mins) X1 20 40 60 20 40 60 Min.
Milling speed (rpm) X2 200 400 600 200 400 600 Min.
Sizes of milling beads (mm) X3 0.1 0.3 1.0 0.1 0.3 1.0 None
Table 3 Preset nanosuspension criteria for the evaluation of dependent variables with numerical optimization of desirability function
Volume of milling beads 100 ml 200 ml
Dependent variable Code Target Goals Target Goals
Submicron sized fraction (%) Y1 Y1 = 100 Max. Y1 = 100 Max.
D [4,3] (µm) Y2 Y2 < 0.600 Min. Y2 < 0.600 Min.
Span Y3 None Min. None Min.
Zeta-potential (mV) Y4 Y4 < -30 Min. Y4 < -30 Min.
Milling temperature (°C) Y5 Y5 < 40 Min. Y5 < 40 Min.
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the effect of dilution on dosage, particle size distribution 
parameters and physical stability.
2.9 Drug content determination of milled ABZ 
suspensions
Albendazole has pH dependent poor water solubility, 
with  a  maximum  at  pH  =  1.2  (see  Subsection  3.4)  as  a 
weak alkaline compound, it was evident to determine the 
amount of active content in highly diluted stock solutions 
at pH = 1.2 (Ph. Eur. 9). Three stock solutions have been 
prepared by adding 0.25 ml of milled ABZ suspensions 
to  0.1  N  hydrochloric  acid  in  250  ml  volumetric  flasks. 
Final volumes were completed to 250 ml (1000 times dilu-
tion) mixed on heatable magnetic stirrer MS - H-S10 (DLAB 




nanosuspensions containing 200.0 mg were calculated from 
the linear calibration of ABZ by UV-Vis spectrophotometry 
on the absorption maximum of albendazole at wavelength 
λmax = 291 nm, measured by an 8453-type UV-Vis spectro-
photometer (Agilent Technologies, USA).
2.10 Short-term physical stability evaluations of 
optimized, milled ABZ nanosuspension
Short-term physical stability evaluation of  the optimized 
formula was tracked by registering particle size distri-
bution parameters and zeta-potential values at predeter-
mined storage intervals: 1, 2, 3, 24, 48, 72, 168, 336, 672, 
1344 hours at 25 °C 60 % (RH) and at 4 °C 60 % (RH) 
storage conditions. Samples were stored in 25 ml volumet-
ric brown vials, protected from direct sunlight. Each sam-
ple was shaken manually for ten seconds prior to inves-
tigations. For particle size distribution and zeta-potential 
measurement settings, see Subsection 2.4.
2.11 Powder X-ray Diffractometry (PXRD), diffraction 
pattern comparison of solids
Diffraction patterns were measured on PANalytical 
X’Pert3 Powder diffractometer (Malvern Panalytical B.V., 
The Netherlands) using Cu Kα radiation with 45 kV accel-
erating voltage and 40 mA anode current over the range of 
5–40 (2 θ) with 0.0084 step size and 99.695 s times per step 
in reflection mode, spinning the sample holder by 1 s−1 rota-
tion speed. Incident beam optics consisted of a programma-
ble divergence slit with 15 mm constant irradiated length 
and an anti - scatter slit at fixed 2. Diffracted beam optics 
consisted  of  X'Celerator  Scientific  ultra-fast  line  detector 
with 0.02 soller slit and programmable anti-scatter slit with 
15 mm constant observed length. Single crystalline silicon 
zero-background diffraction plates were utilized in case 
of diffraction pattern comparisons of raw material ABZ 
powder, albendazole processed in milled and in unmilled 
suspension  forms  after  drying.  Sample  preparations 
involved pouring the milled and unmilled ABZ suspen-
sions into Petri dishes and dried slowly in AccuDry® dry-
ing chamber (Dynatech Scientific Labs, USA) on 40.0 °C, 
for 2 days under air atmosphere and pressure. Dried pow-
ders were gently removed from dishes and sieved through 
a 30 µm mesh size stainless steel sieve (Retsch Technology 
GmbH., Germany) before analysis. Data were collected by 
PANalytical Data Collector Application, version 5.5.0.505 
(Malvern Panalytical B.V., The Netherlands).
3 Results and discussion
3.1 Ideal loading composition determination for wet 
planetary bead milling of albendazole
Milling trial comparisons with d = 1.0 mm sized beads, sur-
factant concentrations of 0.40 % (w/w) Tween 80 and drug 
loadings of 3.00 % (w/w) albendazole revealed, that zirco-
nium-dioxide beads seemed to be the ideal choice, accord-
ing to predetermined criteria (see end of Subsection 2.3). 
There was no difference in milling temperature values; 
it was 29 °C after each milling experiment. 
To increase performance by increasing total contact 
points between surfaces, we switched to d = 0.3 mm sized 
zirconia beads for further investigations. As expected, 
milling temperature values have massively increased 
on 500 rpm milling speed, with continuous operations. 
To offset this phenomenon, various cyclic operations have 
been introduced and compared, in order to keep the mill-
ing temperature as low as possible. We have registered the 
heating and cooldown rates of loadings and found out, that 
based on the utilized milling speed, milling time and con-
tainer size, it took 30-80 minutes to cooldown to room tem-
perature at 200 ml of applied beads. The slow cooldown 
rates were compensated by limited milling time, rotation 
speed to obtain ABZ nanosuspensions. We have compared 
shorter and longer programs, with equally long cooldown 
cycles  (5:5  (mins),  10:10  (mins)  on:  off)  and  continuous 
operations. After 60 minutes of milling sessions, the mill-
ing temperature values were 31.0 °C, 38.0 °C and 60.0 °C 
respectively. Both milling temperature values and particle 
size distribution evaluation results favored the selection 
of 5:5 (mins) (on: off) milling program. Fig. 2 shows the 
Fülöp et al.
Period. Polytech. Chem. Eng., 64(4), pp. 401–420, 2020 |409
results of loading composition optimization for wet plane-
tary bead milling of ABZ.
During a milling process, selection of stabilizer(s) is the 
crucial step for successful accelerated breakdown of raw 
materials (Rehbinder effect) [63, 64] and stabilization of 
newly  formed  nanocrystals,  reported  as  the  first  step  in 
the Quality by Design concept of nanosuspension devel-
opment [56]. In order to compare surface-active agents, 
that were the most ideal for wet planetary bead milling 
of ABZ, two non-ionic (Tween 20 and 80), one anionic 
(SLS)  emulsifiers,  four  triblock  copolymers  (poloxamer 
407 and 188, macrogolglicerol-hidroxystearate, macro-
golglicerol-ricinoleate) and two water soluble polymers 
(PVP K30, HPMC) with low molecular weight values in 
concentrations of 0.40 % (w/w) have been tested. All types 
of surfactants, along with water soluble polymers polox-
amer 407, PVP K30 and HPMC showed promising results. 
Best  performed  emulsifier  however  was  Tween  80  con-
sidering  all  registered  parameters.  It  seemed  emulsifier/
polymer type had no impact on milling temperature val-
ues, 31.0 °C was measured in all cases. Ideal surface-active 
agent (Tween 80) concentration was also screened between 
the concentration rage of 0.30 % (w/w) to 1.00 % (w/w) 
with and without antifoaming agent dimethylpolysiloxane 
in 0.01 % (v/v) at above 0.50 % (w/w) emulsifier, suggested 
by the user's manual of Foamsol.
Above 0.40 % (w/w) Tween 80 submicron sized frac-
tions were about 90 %, highest value (92.89 %) regis-
tered at 0.50 % (w/w) Tween 80 + 0.01 % (v/v) dimeth-
ylpolysiloxane solutions, increasing amount of Tween 80 
had a positive impact on polydispersity (span) values. 
Application of antifoaming agent in this concentration 
slightly increased submicron sized fraction from 86.84 % 
to 92.89 % and had no impact on polydispersity, although 
significantly  improved  milled  suspension  average  yield 
from 50.12 % (w/w) to 60.53 % (w/w) after the separation 
from beads. Ideal drug loading investigations involved the 
screening of 1.00 %, 3.00 % and 4.00 % (w/w) ABZ at 
predetermined best performed conditions. Best-case sce-
nario was the application of 3.00 % (w/w), which yielded 
maximal submicron sized fraction, with minimal polydis-
persity values. Milling temperature values were slightly 
different this time, 28.0 °C, 31.0 °C and 40 °C respectively.
3.2 Effects of milling process parameters
There are numerous interfering critical process parame-
ters responsible for optimal end- product quality e.g. the 




antifoaming agent added to composition
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medium and the inner wall of the milling container, mill-
ing speed, milling time, balls/beads to powder mass ratio, 
volume of the loading, milling atmosphere, milling tem-
perature etc. [65]. The process parameters during labora-
tory scale planetary bead milling process were optimized 
for the development of albendazole containing nanosus-
pension using 3–factor 3–level central composite design 
(face centered of alpha 1) as the response surface method-
ology. A stepwise regression was used to build quadratic 
equations for each response variables. For a design space 
containing 3 factors with 3 levels (33=27 trials), this soft-
ware suggested alpha to be set to 1 and the utilization of 
5 center points in the face centered design. For depen-
dent data analysis transformations were not utilized, the 
software suggested the highest ordered polynomial fitting 
selections, where additional terms were significant and the 
models were  not  aliased,  results  of  lack-of-fit  tests were 
insignificant, as well as adjusted R–squared and predicted 
R–squared values were maximized [66]. 
The response (dependent) variables listed in Table 4 are 
fitted  to a  third-order polynomial model and,  the regres-
sion coefficients for each term in the regression model are 
summarized also in Table 4 along with R–squared and 
precision values of regressions. 
Every design point was well fitted to the polynoms, demon-
strated by the significance of fitted models (p-value < 0.05), 
high  (>  0.85)  coefficient  of  determination  values  and 
high (> 10) signal to noise ratios indicated that, the milling 
experiment have been performed precisely and results were 
reproducible. Statistical significance (p-value < 0.05) of the 
observed parameter was indicated by * symbol.
Subsections 3.2.1–3.2.5  summarize  the  results of  the  in 
depth analysis of process parameters on dependent variables.
3.2.1 Submicron sized fraction (Y1)
Maximizing this parameter is desirable for formulation 
development of nanosuspensions, therefore any factor 
increasing its value considered as positive impact. At 100 
ml applied beads, the main positive effect was the qua-
dratic function of the increasing sizes of milling beads 
(b33), which was offset by the negative effect of the increa-
sing sizes of beads (b3). At 200 ml applied beads, this phen-
omenon was more dominant.
3.2.2 Volume-weighted mean particle size (Y2)
Minimizing this parameter is desirable for formulation 
development of nanosuspensions, therefore any factor 
decreasing its value considered as positive impact. At 100 ml 
applied beads, the main driving effects of particle diminu-
tion were the interaction functions of the milling time and 
sizes of milling beads (b13) and also the milling speed and 
sizes of beads (b23), along with the increasing milling time 
(b1), which was offset by the most dominant negative effect 
of the increasing sizes of milling beads and the minor neg-
ative effect of the quadratic function of milling speed (b22). 
At 200 ml applied beads, the positive effects were the 
Table 4 Polynomial model coefficients and statistical results of analysis based on the 3-factor 3-level face centered composite design (alpha 1) 
(statistical significance of the observed parameter indicated by * symbol, where p-value < 0.05))
Polynomial coefficients/













100 ml 200 ml 100 ml 200 ml 100 ml 200 ml 100 ml 200 ml 100 ml 200 ml
b0 +39.90 +51.13 +1.59 +1.29 +2.28 +2.05 -33.38 -34.47 +34.92 +32.15
b1 +4.13* +3.81* -0.31* -0.26* -0.22* +0.51* -0.83* -0.08 +0.69 +1.19*
b2 +0.07 -0.93 -0.18* +0.23 -0.01 +0.60* +0.66* +1.26* +12.44* +7.97*
b3 -34.78* -34.28* +1.25* +1.05* +0.24* -0.28 -1.88* -3.33* -1.56* +0.97*
b12 +0.04 -1.69 +0.14* +0.06 +0.06 +0.60 -0.48* +1.28* +0.58 +0.62
b13 +0.15 +5.22* -0.35* -0.62* -0.14* -1.07* -0.25 +0.17* +1.04 +1.54*
b23 +2.01* +1.16 -0.27* -0.03 -0.21* -1.21 +1.43* -1.50* -2.25* +1.92*
b11 -0.16 -1.32 +0.14 +0.19 +0.001 -0.28 -1.68* +3.78 -1.74 -0.50
b22 -4.12* -2.16 +0.22* -0.16 +0.04 -0.60 -1.65* +2.64* +1.34 +1.00
b33 +19.81* +13.27* +0.02 +0.32* +0.21* +1.30* +1.18* +6.53* +2.68* +0.83
P–value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 < 0.0001 < 0.0001
R–squared 0.9941 0.9819 0.9739 0.9259 0.9673 0.8547 0.9652 0.9454 0.9347 0.9584
Adj. R–squared 0.9917 0.9744 0.9632 0.8956 0.9539 0.7953 0.9510 0.9230 0.9080 0.9414
Pred. R–squared 0.9861 0.9570 0.9272 0.7774 0.9222 0.5982 0.9113 0.8524 0.8370 0.8944
Adeq. Precision 57.686 33.752 36.226 20.840 37.552 17.615 35.516 22.450 19.258 28.451
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increasing milling time (b1) and the interaction function 
of milling time and sizes of milling beads (b13), which was 
offset by the negative effects of increasing sizes of mill-
ing beads (b3) and the quadratic function of the size of 
milling beads (b33).
3.2.3 Span (polydispersity) values of particle size 
distributions (PSDs) (Y3)
Minimizing this parameter is desirable for formula-
tion development of nanosuspensions, therefore any fac-
tor decreasing its value considered as positive impact. 
At 100 ml applied beads, the main driving effects of reach-
ing homogeneous PSDs were the increasing milling time 
(b1) and the interaction functions of milling time and sizes 
of beads (b13) along with the milling speed and sizes of 
beads (b23), which was nearly compensated by the total 
negative effect of the increasing sizes of milling beads (b3) 
and the quadratic function of the increasing sizes of mill-
ing beads (b33). At 200 ml applied beads, the positive effect 
was the interaction function of the milling time and sizes 
of milling beads (b13), which was outweighed by the total 
negative effects of milling time (b1) milling speed (b2) and 
the quadratic function of the sizes of milling beads (b33).
3.2.4 Zeta-potential values (Y4) of milled ABZ 
suspensions
Minimizing this parameter is desirable for formula-
tion development of nanosuspensions, therefore any fac-
tor decreasing its value considered as positive impact. 
At 100 ml applied beads, the main positive effects were 
the increasing milling time (b1), increasing size of mill-
ing beads (b3), the interaction function of milling time 
and milling speed (b12) and the quadratic functions of 
the milling time (b11) along with the milling speed (b22). 
These effects were not compensated by the negative effects 
of the increasing milling time (b2), the interaction func-
tion of the milling speed and sizes of milling beads (b23) 
and the quadratic effect of the sizes of milling beads (b33). 
At 200 ml applied beads, positive effects of the increasing 
sizes of milling beads (b3) and the interaction function of 
the milling speed and sizes of milling beads (b23), were off-
set by the total negative effects of the increasing milling 
speed (b2), the interaction functions of the milling time and 
milling speed (b12) along with the milling time and sizes of 
milling beads (b13) and also the quadratic functions of the 
milling speed (b22) and sizes of milling beads (b33).
3.2.5 Milling temperature values (Y5)
Minimizing this parameter is desirable for formula-
tion development of nanosuspensions, therefore any fac-
tor decreasing its value considered as positive impact. 
At 100 ml applied beads, the main positive effects were the 
increasing sizes of milling beads (b3) and the interaction 
function of the milling speed and size of milling beads (b23), 
which was overcompensated by the total negative effects of 
the increasing milling speed (b2) and the quadratic func-
tion of the sizes of milling beads (b33). At 200 ml applied 
beads, only negative effects were observed, the major one 
was the increasing milling speed (b2). 
When influence of zirconia beads with different sizes 
were compared on milled ABZ particle size distribution 
parameters and suspension zeta-potential values at 100 ml 
of applied zirconia beads, result showed improving per-
formance on size reduction with the utilization of smaller 
beads, consequently showed inverse proportionality with 
the size of milling medium. Nanosuspension criteria 
(see end of Subsection 2.5) were easily fulfilled with the 
application of d = 0.1 mm sized beads at low to medio-
cre milling speed intervals (200–434 rpm), with a wide 
range in process time (20–59.4 mins), however coarse pro-
grams at higher rotation speeds (500 - 600 rpm) seemed 
to deteriorate results (Fig. 3). For explanation we should 
look at the 3-Dimensional response surface plots (Fig. 4). 
Low energy bead milling with 100 ml of applied amount 
of d = 0.1 mm sized zirconia beads was effective below 
Fig. 3 Contour plot of the nanosuspension criteria by numerical 
optimization of desirability function, where x marks the chosen process 
parameters: 300 rpm rotation speed, 30 minutes long operation, with 
100 ml of X3: d = 0.1 mm sized zirconia milling beads applied
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400 rpm, at this rotation speed value submicron sized 
fraction was maximal (100 %) and volume weighted mean 
particle size (D[4,3]) was minimal (0.192 µm), due to max-
imal specific surface area of ABZ nanocrystals, this is also 
the point, where mean zeta-potential value was maximal 
(−30.5 mV). Above 400  rpm  rotation  speed,  aggregation 
due to increased thermal motion at higher milling tem-
perature values (36.0–39.0 °C), can be observed, probably 
due to growing bead-bead collisions.
Milling trials with d = 0.3 mm and d = 1.0 mm sized beads 
showed less promising results compared to d = 0.1 mm 
beads, even tendencies were different, unlike d = 0.1 mm 
sized beads, prolonged, coarse operations yielded the best 
results considering volume-weighted mean particle sizes 
1.600 µm for d = 0.3 mm and 2.200 µm for d = 1.0 mm 
sized beads. Thus, prolonged operations are advisable for 
the development of ABZ nanosuspension by low energy wet 
bead milling method with the utilization of larger zirconia 
beads (d = 0.3 mm, d = 1.0 mm) at higher milling speed 
values. In contrast application of smaller zirconia beads 
(d = 0.1 mm) are favored at lower to mediocre milling speeds, 
which yielded ABZ nanosuspension in a shorter process.
Utilization of 200 ml applied volume of milling beads 
the same aggregation tendency can be registered at higher 
mechanical energy input for d = 0.1 mm (Fig. 4) and even 
for d  =  0.3  beads,  resulted  in  a  significant milling  tem-
perature escalation from previously measured 39.0 °C 
to 49.9 °C for d = 0.1 mm and 44.5 °C for d = 0.3 mm 
sized beads with  higher  zeta-potential  values > −26 mV 
for d = 0.1 mm and > −33 mV for d = 0.3 mm observed 
compared to the mean zeta-potential value (< −30.5 mV) at 
lower amount of beads applied previously. Preset nanosus-
pension  criteria  (see Subsection 2.5)  excluded  the  appli-
cation of higher amount of zirconia beads, due to higher 
zeta-potential values of milled ABZ suspensions.
Summarizing  optimization  results,  we  can  report, 
that ideal loading consisted of 0.64 % (w/w) ABZ, 
20.60 % (w/w) surfactant solution, containing 0.50 % (w/w) 
Tween 80 mixed with 0.01 % (v/v) dimethylpolysiloxane 
as antifoaming agent, 78.76 % (w/w) d = 0.1 mm sized zir-
conia beads of the total mass loading at a batch size of 
476.1498 g, loaded in stainless steel container capacity of 
500 ml. As for ideal chosen settings, milling speed was 
300  rpm with  30 minutes  long  5:5  cyclic, milling  oper-
ation. Milling temperature at the end of the process was 
26.0 °C, showed a minimal + 8.0 °C elevation compared to 
the temperature of starting surfactant solution.
The validation of responses predicted by the design 
model shall be performed in the final step. This is done by 
conducting confirmatory trials using RSM (response sur-
face methodology) and the results are critically evaluated. 
Based on the trial results the optimal process parameters 
are set for manufacturing of the product [35, 67]. Validation 
trials were performed selecting the borderline points of the 
highlighted region of the contour plot (Fig. 3) including 
the point, which contributed to the optimized formulation 
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parameters. Maximal relative standard deviation was cal-
culated at verification trial No. 3., between actual and pre-
dicted mean span values (11.03 %), other noticeable differ-
ences were registered at verification trial No. 1., between 
actual and predicted mean milling temperature values 
(7.41 %),  at  verification  trial No.  5.,  between  actual  and 
predicted  mean  size  values  (6.48 %)  and  at  verification 
trial No. 6., between actual and predicted mean zeta-po-
tential values (7.38 %) (Table 5). The fitted model demon-
strated good predictions in overall and could be used for 
critical process parameter optimization.
3.3 Comparison of the particle size distribution 
parameters of raw material ABZ powder and 
optimized ABZ nanosuspension
Laser diffraction measurements have been performed to val-
idate the mean particle size provided by the supplier (> 90 
% less, than 30 µm) of raw material albendazole powder 
after dispersing 3.00 % (w/w) ABZ to 0.5 % (w/w) Tween 
80 and 0.01 % (v/v) dimethylpolysiloxane aqueous-based 
surfactant solution at a mixing speed of 600 rpm, homog-
enization time 5 minutes on heatable magnetic stirrer 
MS-H-S10 (DLAB Instruments Ltd., China) at  room tem-
perature. Results demonstrated, that the < 30 µm sized frac-
tion was 88.82 ± 0.561 % and volume-weighted mean size D 
[4,3] of 28.787 ± 3.0520 µm. Optimized, milled ABZ nano-
suspension formulation yielded ~ 145.39 times reduction in 
mean size, ~ 14.93 times in mean polydispersity (span value) 
(Fig. 5), ~ 18.47 times improvement in specific surface area, 
~ 9.55 times boost in submicron sized fraction compared 
to unmilled ABZ surfactant dispersion. Freshly prepared 
end-product was also characterized by DLS and ELS met-
hods  as well,  confirming  the  completion  of  predetermined 
nanosuspension criteria, with intensity-weighted mean size 
(Z AVG d) of 173.5 ± 0.97 nm, polydispersity index (PDI) of 
0.175± 0.0120 and zeta-potential of −38.2 ± 0.83 mV.
3.4 Comparison of the thermodynamic solubility values 
of starting material ABZ powder, Tween 80 dispersion 
and optimized, milled nanosuspension
We have confirmed previous observations of Torrado et al. [5], 
that ABZ has pH dependent, poor water solubility, low-
est value registered in medium at pH = 6.80, which was 
7.3675 ± 0.62803 µg/ ml, solubilization with 0.50 % (w/w) 
Tween 80 solution enhanced ABZ initial solubility to 
25.5165 ± 0.26791 µg/ ml and gained a 2.46 - folds boost. 
Optimized, milled nanosuspension formula further 
improved performance and showed 62.5144 ± 0.04845 µg/ml 
solubility, raised it 1.45-folds compared to unmilled surfac-
tant dispersion. In medium at pH = 4.50 the impact of mean 
solubility gains were slowly diminishing, initial solubility of 
raw ABZ powder 11.4917 ± 0.15958 µg/ ml was increased to 
57.9846 ± 2.71380 µg/ml, which was a 4.05-folds boost due 
to solubilization and optimized milling operation demon-
strated 65.9163 ± 0.05412 µg/ ml value, showed a 13.68 % 
boost compared to unmilled dispersion. Least gains in solu-
bility were noticeable in medium at pH = 1.20, where initial 
solubility of ABZ was maximal 863.3964 ± 3.72777 µg/ ml, 
which was elevated to 1010.5110 ± 2.66921 µg/ ml, boosted 
by 17.04 % due to solubilization and particle size reduction 
raised it further to 1269.7990 ± 2.42509 µg/ ml, and gained 
a 25.66 % boost compared to unmilled dispersion (Fig. 5). 
3.5 Comparison of the in-vitro dissolution profiles
Dissolution rate constants have been calculated con-
sidering thermodynamic solubility values measured in 





























1 20 400 0.1
Predicted 93.35 0.453 2.331 -33.07 37.76
Actual 97.00 0.400 2.300 -33.1 34.00
2 40 200 0.1
Predicted 92.31 0.584 2.100 -31.19 25.81
Actual 90.21 0.6 2.100 -31.5 24.00
3 40 400 0.1
Predicted 94.49 0.304 2.252 -30.31 39.15
Actual 98 0.260 2.180 -31.30 37.00
4 60 400 0.1
Predicted 98.31 0.254 2.175 -30.92 37.07
Actual 100 0.262 2.150 -31.30 37.00
5 60 200 0.1
Predicted 96.09 0.625 1.962 -31.32 23.13
Actual 93.69 0.685 2.000 -31.00 24.00
6 30 300 0.1
Predicted 99.41 0.205 0.900 -34.41 28.00
Actual 100 0.189 0.864 -38.20 26.00
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appropriate media, lag times and shape parameter values 
with Weibull model fitting on measured dissolution points 
(Table 6 and Fig. 6).
3.6 Drug content and impact of the washing of beads 
and dilution on particle size distribution parameters 
and zeta-potential values of milled ABZ suspensions
By simply pouring the optimized ABZ nanosuspension on 
sieve and separating it from beads, mean ABZ yield was low 
60.53 ± 3.485 % (Table 7). It contained 200.000 ± 0.3438 
mg of ABZ in 5.471 cm3 volume. Washing the beads after 
milling operations with different amounts of 0.50 % (w/w) 
Tween 80 and 0.01 % (v/v) dimethylpolysiloxane contain-
ing aqueous-based surfactant solutions have demonstrated, 
that increasing amount of Tween 80 added to milled sus-
pensions slightly increased particle size distributions 
parameters and decreased zeta-potential values, while 
submicron sized fractions were permanent, which can be 
explained by the steric stabilization effect of Tween 80. 
Best case scenario was the additional 33.33 % (w/w) sur-
factant solution of total mass loading added to milled ABZ 
suspension, where reasonable ABZ yield 83.05 ± 2.783 % 
was achieved, in a relatively low mean dose of 7.094 cm3. 
This diluted ABZ nanosuspension was then subjected to 
short-term physical stability evaluations. 
3.7 Short-term physical stability evaluations of 
optimized ABZ nanosuspension
Short-term  physical  stability  of  optimized  formula  was 
characterized by recording particle size distribution 
parameters with both LD and DLS methods at predeter-
mined time points (Fig. 7). The volume-weighted mean 
particle size (D[4,3]) and intensity-weighted mean particle 
size (Z AVG d) values were the most sensitive to aggre-
gation. Results demonstrated, that refrigerated conditions 
were more suitable for storage of ABZ nanosuspensions, 
Fig. 5 Impact of volume weighted mean particle size (D[4,3]) on mean thermodynamic solubility values of ABZ (mean ± SD, n=3)
Table 6 Influence of particle size reduction and solubilization of ABZ on fitted dissolution rate constants (k), n = 3, mean values ± SDs
Sample ABZ powder ABZ Tween 80 dispersion Optimized ABZ nanosuspension
Medium t0 (min)
k (min)−1 ± 
SD
R2 t0 (min)
k (min)−1 ± 
SD
R2 t0 (min)
k (min)−1 ± 
SD
R2
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micro sized aggregates have been detected by LD at 
56 days of storage, under refrigerated conditions. At room 
temperature however, micro sized aggregates have been 
observed much sooner at 28 days of storage. 
3.8 Diffraction pattern comparison of raw ABZ powder 
and processed in dried, milled suspensions
Our experimental PXRD results in agreement with previ-
ous ones by Chattah et al. [10] and Pranzo et al. [13] have 
demonstrated, that raw ABZ powder consisted of both 
polymorphic forms of ABZ, Form I and Form II (Fig. 8). 
Most intensive Form I main, characteristic peaks can be 
identified  at  positions  of  6.9°,  11.3°,  11.6°,  17.9°,  24.4°, 
and 27.2° (2° θ). Form II main peaks were also consistent 
with the literature located at 7.3°, 10.7°, 14.6°, 18.1°, 24.7°, 
25.6° and 30.5° (2° θ) positions. It seemed drying had no 
effect on ABZ polymorphy, dried, optimized, milled ABZ 
nanosuspension also contained both forms. We've reached 
higher milling temperature values at higher amount of 
milling beads applied (200 ml), especially with the uti-
lization of d = 0.3 mm sized ones during coarse milling 
programs (involving 600 rpm milling speeds and at least 
60 minutes long operations). For demonstration of extreme 
conditions, a 180 minute long operation was tested in a 
Table 7 Influence of beads washing and dilution on final ABZ yield, particle size distribution parameters, zeta-potential values and dose of 
optimized, milled ABZ nanosuspension, n = 3, mean values ± SDs
Washing with additional optimal surfactant solutions of total mass loading (% w/w)
Parameter Optimized milled nanosuspension 16.67 2 x* 16.67 33.33 2*33.33
Yield (%) 60.53 ± 3.485 70.90 ± 3.245 86.00 ± 2.850 83.05 ± 2.783 86.00 ± 2.670
Z AVG d (nm) 173.500 ± 0.9702 183.475 ± 0.1732 174.300 ± 1.4450 182.200 ± 1.3130 178.800 ± 2.6990
PDI 0.175 ± 0.0120 0.191 ± 0.0080 0.183 ± 0.0100 0.187 ± 0.0160 0.190 ± 0.0080
Zeta-potential (mV) -38.20 ± 0.830 -38.13 ± 0.928 -37.60 ± 0.576 -51.90 ± 0.465 -41.80 ± 0.907
D[4,3] (µm) 0.189 ± 0.0022 0.190 ± 0.0010 0.193 ± 0.0015 0.194 ± 0.0005 0.204 ± 0.0004
Span 0.864 ± 0.0198 0.977 ± 0.0022 0.902 ± 0.0016 0.923 ± 0.0041 1.006 ± 0.0093
Dose (200 mg) in 
volume (ml) 5.471 ± 0.0094 6.373 ± 0.1378 6.851 ± 0.0671 7.094 ± 0.0238 7.978 ± 0.1247
Fig. 6 Comparison of the fitted in-vitro dissolution profiles of optimized, milled ABZ nanosuspension (○), unmilled surfactant dispersion (∆) 
and ABZ powder (□) in various, aqueous based buffer solutions (pH=1.2, pH=4.5, pH=6.8), n = 3, mean values ± SDs
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stainless steel container with capacity of 500 ml among 
previously described settings, without complete conver-
sion  of  Form  I  to  Form  II  registered.  So,  50  °C milling 
temperature during a 180 minute long session was not 
enough for the detection of only Form II characteristic 
peaks. By switching container sizes from 500 ml to 50 
ml and therefore, increasing thermal inertia (lowering 
the total volume of cooling surfactant solution present in 
the container) milling programs involving various pro-
cess times (30 minutes, 60 minutes, 180 minutes) were 
compared. As expected, milling temperature values have 
massively increased to 60.0 °C, 65 °C, and 72 °C respec-
tively, which was enough for triggering total conversion of 
ABZ Form I to Form II in a short amount of time (30 min-
utes). Conversion was noticeable from the shifted colors of 
milled suspensions from pale white to brown.
4 Conclusions
Based on QbD approach, ABZ containing nanosuspen-
sion was prepared with top-down low energy plane-
tary bead milling. Optimized formula showed less, than 
200 nm mean size with narrow distribution (PDI < 0.200), 
which can easily compete with the results of newly devel-
oped 'bottom-up' nanoparticle production techniques. 
Statistical results of optimization suggested the selection of 
d = 0.1 mm sized zirconia beads in lower (100 ml) volume, 
at low to mediocre milling speed intervals (200 – 434 rpm) 
up to a maximum of 40 minutes long milling operations. 
The utilization of ABZ nanocrystals proved to increase 
thermodynamic solubility values in all tested media, 
which  was  most  efficient,  where  initial  solubility  was 
minimal. On the contrary improvement of dissolution rate 
values were the most prominent, where initial solubility 
was maximal. No lag time values were observed in the 
Fig. 8 Comparison of the diffraction patterns of raw material ABZ powder and ABZ processed in dried, milled suspensions
Fig. 7 Influence of storage conditions and time on mean particle size 
values of optimized, milled ABZ nanosuspensions measured by LD 
and DLS methods, n = 3, mean values ± SDs
Fülöp et al.
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dissolution kinetics of the nanosuspension in comparison 
with the unmilled and raw powder samples.
Washing the beads after milling with 33.33 % (w/w) 
of total mass loading with surface active agent solutions 
and mixed with ABZ nanosuspensions have demonstrated 
reasonable ABZ yield (83.05 %), in a relatively low mean 
dose of 7.094 cm3. Without solidification micrometer sized 
aggregates have appeared at 28 days of storage at room 
temperature and at 56 days at refrigerated conditions.
PXRD studies revealed, that the optimized product 
contained both polymorphs, so there was no recrystalliza-
tion due to careful evaluation of loading composition and 
milling parameters. Although extreme milling conditions 
have been identified, where undesirable full polymorphic 
conversion of ABZ from Form I to Form II has been real-
ized. Critical conditions included the application of d = 0.3 
mm sized zirconia beads, in high volume (200 ml), loaded 
in a smaller milling container (50 ml) and with the utiliza-
tion of coarse milling programs involving 600 rpm rota-
tion speeds and 30-180 minutes long operations.
Abbreviations
1 ABZ – Albendazole
2 PXRD – Powder X-Ray Diffractometry




6 DOE – Design of Experiments
7 QbD – Quality by Design
8 OVAT – One variable at a time
9  WSSM – Wet stirred media milling
10 HPH – High pressure homogenization
11 D[4,3] – Volume-weighted mean particle size (De 
Brouckere Mean Diameter)
12 AF – Antifoaming Agent
13  SLS – Sodium Laurylsulphate





18  Span  –  Polydispersity,  width  of  a  particle  size 
distribution
19 Z AVG d – Intensity-weighted mean particle size
20 PDI – Polydispersity index
21  ELS – Electrostatic Light Scattering
22  PES – Polyether sulfonate
23 RH – Relative Humidity
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